FIELD: chemistry.
SUBSTANCE: present invention relates to a compound represented by Formula (I), in which X represents O, Y represents CR5, R1 and R2 each represent a hydrogen atom, R3 represents a hydrogen atom, R4 represents C1- 6 alkyl group substituted with methoxy, R5 represents a fluorine atom, ring A represents: , or its salts. Also the following is proposed: an individual compound - 2-fluoro-4-((3-((3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl)-4-oxo-3,4,8,9-tetrahydro-2H-benzofuro[5,4-e][1,3]oxazin-6-yl)methyl)-N-(2-methoxyethyl)benzamide or its salt, drug, method for positive allosteric modulation of the cholinergic muscarinic receptor M1, method for prevention or treating constipation in a mammal and using these compounds in the preparation of a prophylactic or therapeutic agent for constipation.
(I)
EFFECT: present compounds have positive allosteric modulator activity of the cholinergic M1 muscarinic receptor and may be useful for the prevention or treatment of constipation and equal.
9 cl, 6 tbl, 11 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC COMPOUND | 2018 |
|
RU2791533C2 |
AGENT FOR PROPHYLAXIS AND TREATMENT OF NEUROPATHY | 2003 |
|
RU2337682C2 |
HETEROCYCLIC COMPOUND | 2017 |
|
RU2748693C2 |
HETEROCYCLIC COMPOUND | 2018 |
|
RU2773441C2 |
HETEROCYCLIC COMPOUND | 2019 |
|
RU2786587C2 |
HETEROCYCLIC COMPOUND | 2018 |
|
RU2768473C2 |
HETEROCYCLIC COMPOUND | 2018 |
|
RU2780892C2 |
GROWTH INHIBITOR | 2019 |
|
RU2825665C2 |
HETEROCYCLIC COMPOUND | 2019 |
|
RU2815003C2 |
CONDENSED CYCLIC COMPOUNDS | 2007 |
|
RU2444521C2 |
Authors
Dates
2023-10-31—Published
2019-09-27—Filed